We are in no way endorsing this trial only making the information available...
If you have questions please contact the person listed below. I am only posting this to share and am not affiliated with this clinical trial....
My name is David Morgenstern and I am Director of Clinical Affairs for Endocyte, a biotech company located in Indiana . Endocyte is sponsoring a Phase II study called PRECEDENT for women with platinum-resistant ovarian cancer. I met with Pat Goldman and Diane O’Connor from the Ovarian Cancer National Alliance recently about getting the word out to the ovarian cancer advocacy and support community about the PRECEDENT study. They suggested I reach out directly to the local Alliance partners. I’m not looking for an endorsement or recommendation from your organization, but we do have a couple of clinical trial sites in Florida (Dr. Schimp at MD Anderson in Orlando and Dr. Arevalo-Araujo at Pasco Pinellas Cancer Center) and I’m hoping that there’s a way that we can get the word out about the study to as many women with ovarian cancer statewide so that they can see if this is something that might be of interest to them.
There’s information about PRECEDENT on Endocyte’s website at http://www.endocyte.com/clinical.html and a detailed description of the study at
http://www.clinicaltrials.gov/ct2/show/NCT00722592?term=NCT00722592&rank=1
David E. Morgenstern, PhD
Director, Clinical Affairs
Endocyte, Inc.
Indianapolis office: (317) 876-1478 x104
Clinical fax line: (765) 464-8028
dmorgenstern@endocyte.com
www.endocyte.com
Already a member? Sign in
Welcome to Inspire!
What - Inspire is a place where you can connect with people who share your health concerns and find information and advice in groups sponsored by organizations you know and trust.
Why - As a member you can use Inspire to let friends and family know how you're doing, contact others who share your health concerns, receive personalized updates and information about participating in surveys and clinical trials, and more.
How - Joining Inspire is completely free and usually takes less than a minute. Join now!
Endocyte PRECEDENT Study
- By kss1204
- Posted April 18, 2009 at 12:56 pm · 3 replies
- In Clinical trials
- Shared with the public
- Edited April 19, 2009 at 10:47 am
Explore topics in this discussion:
3 replies
- Oldest first
- Newest first
- By Gia
- Posted April 19, 2009 at 6:34 am
- Report post
Dr. Morgenstern, Thank you for the information, I personally appreciate all information about potential ovarian cancer studies. I do have a question about the molecular imaging used to assure the drug/folate receptor is active for lack of a better word. I am thinking this involves injection of contrast material or something of that nature--is that correct and if so how often during the study does the candidate go through that procedure. As you know we receive multiple CT scans with contrast materials and I for one am concerned about the total number of these procedures. Do you feel that is an issue? Gia
- By kss1204
- Posted April 19, 2009 at 10:47 am
- Report post
If you have questions please contact the person listed below. I am only posting this to share and am not affiliated with this clinical trial.
There’s information about PRECEDENT on Endocyte’s website at http://www.endocyte.com/clinical.html and a detailed description of the study at
http://www.clinicaltrials.gov/ct2/show/NCT00722592?term=NCT00722592&rank=1
David E. Morgenstern, PhD
Director, Clinical Affairs
Endocyte, Inc.
Indianapolis office: (317) 876-1478 x104
Clinical fax line: (765) 464-8028
dmorgenstern@endocyte.com
www.endocyte.com
Add to the discussion